- Previous Close
1.2200 - Open
1.1900 - Bid 1.1100 x 100
- Ask 1.2400 x 100
- Day's Range
1.1000 - 1.1900 - 52 Week Range
1.1000 - 19.5410 - Volume
371,779 - Avg. Volume
699,281 - Market Cap (intraday)
74.131M - Beta (5Y Monthly) 2.22
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0700 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.80
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
www.macrogenics.comRecent News: MGNX
View More
Performance Overview: MGNX
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGNX
View MoreValuation Measures
Market Cap
76.97M
Enterprise Value
-87.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.52
Price/Book (mrq)
0.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-44.65%
Return on Assets (ttm)
-24.68%
Return on Equity (ttm)
-49.85%
Revenue (ttm)
149.96M
Net Income Avi to Common (ttm)
-66.97M
Diluted EPS (ttm)
-1.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
201.67M
Total Debt/Equity (mrq)
32.28%
Levered Free Cash Flow (ttm)
-32.49M
Research Analysis: MGNX
View MoreResearch Reports: MGNX
View MoreDaily – Vickers Top Buyers & Sellers for 10/05/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/12/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/05/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.